Here's what we'll cover
Here's what we'll cover
What Lilly's Earnings Beat Actually Tells You
Eli Lilly just reported one of its strongest financial quarters in recent memory, with revenue climbing roughly 48% compared to the same period a year ago. The headline numbers are impressive from a Wall Street perspective, but if you are a patient taking Mounjaro or considering Zepbound, the more relevant question is: what does this mean for you?
The short answer is that booming sales reflect real-world demand. Millions of people are finding these medications effective, and Lilly is investing heavily to meet that demand. That investment has direct implications for supply availability, manufacturer savings programs, and the competitive landscape among GLP-1 providers.
Understanding the business context helps you become a more informed patient and a sharper consumer of healthcare.
What Is Driving the Revenue Surge?
Both Mounjaro and Zepbound contain the same active ingredient: tirzepatide. Mounjaro is FDA-approved for type 2 diabetes management, while Zepbound received FDA approval specifically for chronic weight management in adults with obesity or weight-related health conditions.
The two medications together account for the bulk of Lilly's revenue growth. Demand has outpaced most analyst projections, suggesting that more patients are being prescribed tirzepatide than Wall Street anticipated, and that those patients are staying on the medication long enough to drive recurring sales.
Why Tirzepatide Demand Is So Strong
Tirzepatide works differently from older GLP-1 medications like semaglutide. It activates two hormone receptors at once: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-action mechanism appears to produce greater average weight loss in clinical trials compared to GLP-1-only medications.
In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide lost an average of around 22% of their body weight over 72 weeks. Results like these are driving strong word-of-mouth and growing prescriber confidence, which feeds directly into the kind of demand surge reflected in Lilly's latest earnings.
Supply Shortages: Is the Situation Improving?
One of the most frustrating experiences for patients over the past two years has been inconsistent supply. Both Mounjaro and Zepbound appeared on the FDA's drug shortage list for extended periods, leaving patients scrambling to find their doses at local pharmacies.
Lilly has been investing in expanded manufacturing capacity, and the record sales figures suggest the company has strong financial incentive to keep scaling production. The FDA removed tirzepatide from its official shortage list earlier in 2024, though real-world availability has varied by dose and region.
What This Means at the Pharmacy Counter
If you have had trouble filling your prescription in the past, the news is cautiously better. Major pharmacy chains are reporting more consistent stock of common doses. However, supply can still fluctuate, especially for higher doses like 10 mg and 15 mg.
Practical tips to improve your chances of consistent access:
- Ask your pharmacist to hold stock or flag your prescription in advance.
- Use a mail-order or specialty pharmacy, which may have more reliable inventory.
- Talk to your prescriber about whether a slightly lower dose remains therapeutically appropriate if your usual dose is temporarily unavailable.
What Lilly's Growth Means for Pricing and Savings
Record revenue does not automatically mean lower prices for patients. The list price for branded Zepbound runs over $1,000 per month without insurance coverage, a figure that excludes most uninsured or underinsured patients from access without assistance.
That said, Lilly has maintained savings programs that can significantly reduce out-of-pocket costs for eligible patients.
Current Savings Options Worth Knowing
You can explore additional savings options through GLP-1 Coupons compiled specifically for patients navigating the cost of these medications.
How This News Affects the Competitive Landscape
Lilly's financial success puts additional pressure on Novo Nordisk, the maker of Ozempic and Wegovy (semaglutide). Novo Nordisk has faced its own challenges with supply and pricing, and Lilly's strong earnings signal that tirzepatide is taking meaningful market share.
For patients, this competition is largely a positive development. When two major pharmaceutical companies compete aggressively in the same therapeutic space, it tends to drive investment in patient support programs, provider education, and eventually pricing pressure over time.
What About Compounded Tirzepatide?
Because tirzepatide was previously on the FDA shortage list, compounding pharmacies were legally permitted to produce copies of the drug. The FDA's removal of tirzepatide from the shortage list changed the regulatory picture significantly.
Lilly has taken legal action against compounding pharmacies continuing to sell tirzepatide copies. If you have been using a compounded version, it is important to speak with your prescriber about your options, including transitioning to the branded medication through a patient savings program. Compounded medications are not FDA-approved and may vary in potency and purity.
What Questions Should You Ask Your Doctor?
Lilly's strong sales data reinforces that tirzepatide is a widely used and clinically supported option for both diabetes management and weight loss. But strong commercial performance does not replace a personalized conversation with your provider.
Here are specific questions worth raising at your next appointment:
If you are currently taking Mounjaro for diabetes:
- Is my current dose still appropriate given my latest A1C and weight trends?
- Could I benefit from transitioning to Zepbound if weight loss is also a goal?
- What does my insurance cover, and are there better savings options available?
If you are considering starting a GLP-1 medication:
- Am I a better candidate for tirzepatide (Mounjaro/Zepbound) or semaglutide (Ozempic/Wegovy) based on my health history?
- What side effects should I watch for in the first few weeks?
- How do we define success at 3 months, 6 months, and one year?
Finding the right provider to have these conversations is as important as choosing the right medication. You can compare GLP-1 providers to find one who specializes in these medications and can guide your treatment plan.
Comparing Tirzepatide and Semaglutide: A Quick Reference
If you are still weighing your options between the two leading GLP-1 medication classes, here is a side-by-side comparison based on currently available clinical and regulatory information.
This comparison is meant to inform a conversation with your provider, not replace one. Individual response to these medications varies, and your medical history matters greatly in determining which option is right for you.
No waiting list. No insurance needed.
Frequently Asked Questions
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound both contain tirzepatide, but they are FDA-approved for different conditions. Mounjaro is approved for type 2 diabetes management, while Zepbound is approved specifically for chronic weight management in adults with obesity or weight-related conditions. Your insurance coverage may differ significantly between the two.
Why did Lilly's revenue surge so much in 2025-2026?
Eli Lilly's revenue surge was driven primarily by strong and growing demand for tirzepatide under the brand names Mounjaro and Zepbound. Both medications have shown strong clinical results, and prescriptions have grown faster than most analysts predicted as more patients and providers become familiar with the treatment.
Is tirzepatide still available, or is there still a shortage?
The FDA officially removed tirzepatide from its drug shortage list in 2024. Availability has improved significantly, though individual pharmacy stock can still vary by dose and location. Mail-order pharmacies and specialty pharmacies often have more consistent inventory than retail chains.
How much does Zepbound cost without insurance?
The list price for Zepbound is over $1,000 per month without insurance. However, Lilly offers a savings card that can reduce the cost to as low as $25 per month for commercially insured patients. Uninsured patients may qualify for patient assistance programs based on income.
Is compounded tirzepatide still legal to purchase?
The legal landscape for compounded tirzepatide changed after the FDA removed it from the shortage list. Compounding pharmacies are generally no longer permitted to produce copies of non-shortage drugs. Lilly has pursued legal action against some compounders. If you are using a compounded version, speak with your prescriber about transitioning to the branded product.
How does tirzepatide compare to semaglutide for weight loss?
In clinical trials, tirzepatide produced greater average weight loss than semaglutide, with the highest doses resulting in roughly 20-22% body weight reduction compared to approximately 15% for the highest dose of semaglutide. That said, individual results vary, and both medications are effective for many patients.
The Bottom Line for Patients
Eli Lilly beating earnings forecasts is a business story, but it has real implications for anyone navigating GLP-1 medications. The 48% revenue surge reflects genuine, sustained patient demand for tirzepatide, and that demand is reshaping the market in ways that matter at the prescription counter.
Supply is more stable than it was a year ago. Competition between Lilly and Novo Nordisk is pushing both companies to improve patient access programs. And the clinical case for tirzepatide continues to grow stronger as more long-term data becomes available.
At the same time, cost remains the most significant barrier for most patients. Strong earnings at Lilly headquarters do not translate to lower prices at your pharmacy unless you are actively using available savings programs and asking your provider the right questions.
What to Do Next
If you are currently taking Mounjaro or Zepbound, now is a good time to review your savings options and confirm you are on the most cost-effective path for your insurance situation.
If you are evaluating whether to start a GLP-1 medication, the broader availability of tirzepatide and improved supply chains mean access is meaningfully better than it was in 2023 or 2024. The key is working with a knowledgeable provider who can match the right medication to your specific health profile.
GLP-1.com is built to help you make that process easier. You can compare leading GLP-1 providers, review current GLP-1 coupons and savings programs, and get detailed medication breakdowns for Ozempic, Wegovy, and Mounjaro all in one place.
As always, consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication. The information here is intended to support that conversation, not replace it.